Abstract Certain tumors, such as breast, frequently metastasize to bone where they can induce bone destruction. Currently, it is well-accepted that the tumor cells are influenced by other cells and growth factors present in the bone microenvironment that lead to tumor-induced bone disease. Over the past 20 years, many groups have studied this process and determined the major contributing factors; however, these results do not fully explain the changes in gene expression and cell behavior that occur when tumor cells metastasize to bone. More recently, groups studying metastasis from soft tissue sites have determined that the rigidity of the microenvironment, which increases during tumor progression in soft tissue, can regulate tumor cell behavior and gene expression. Therefore, we began to investigate the role of the rigid bone extracellular matrix in the regulation of genes that stimulate tumor-induced bone disease. We found that the rigidity of bone specifically regulates parathyroid hormone-related protein (PTHrP) and Gli2 expression in a transforming growth factor β (TGF-β) and mechanotransduction-dependent mechanism. In this review, we summarize the mechanotransduction signaling pathway and how this influences TGF-β signaling and osteolytic gene expression.
can cause changes in gene expression that drive tumor cell production of osteolytic factors [2, 3] . While many groups have identified several relevant pathways that promote bone destruction, our work has focused on the production of PTHrP that stimulates osteoclast-mediated bone resorption and the release of TGF-β. This release of TGF-β from the bone matrix further stimulates PTHrP expression, causing a further stimulation of bone destruction.
It is now well understood that communication occurs not only between the tumor cells and bone, but also includes other cell types, such as immune cells and stromal cells. Additionally, the physical microenvironment of the bone may contribute to changes in tumor and bone cell behavior. Taking this into account helps explain the unique characteristics of tumor cell gene expression and behavior when tumor cells metastasize to bone.
The Bone Micro-Environment
Bone is a unique microenvironment that is different than any other tissue in the body. One of the major differences between bone and soft tissue is the rigidity of the mineralized extracellular matrix, which is approximately 1,000,000 times more rigid than normal breast tissue. The rigid bone matrix not only causes physical constraints on tumor growth, but it also alters both tumor cell gene expression and tumor cell response to growth factors [4] . While the rigid mineralized extracellular matrix is a major factor in the regulation of tumor cell gene expression, other characteristics of the bone microenvironment, such as stromal cells, may also mediate the behavior of the tumor cells when they become established in bone. Bone marrow stroma is a diverse population of cells that consists of precursor cells, immune cells, and fibroblasts. There is sufficient evidence from many different studies that each of these cell types significantly contributes to the overall gene expression and behavior of tumor cells that metastasize to bone [5] .
Growth Factors
While bone is frequently considered to be an organ made of primarily structural proteins, it is also a vast storage site for many different growth factors, such as TGF-β, BMPs, Wnts, and Insulin-like growth factor (IGFs). As osteoclasts resorb the extracellular matrix, the release of these growth factors potentially affects tumor cell growth and behavior. Each of these factors contributes to physiological bone formation in different ways, and all are likely involved in tumor-induced bone disease; however, the role of TGF-β in this process has been studied most extensively. For example, TGF-β released during bone destruction stimulates the expression of the transcription factor Gli2 leading to increased expression of PTHrP [6] .
TGF-β has a complicated role both in the regulation of tumor growth and in bone formation. In the regulation of tumor growth, TGF-β is well-documented to play an important biphasic role, wherein it inhibits proliferation of normal cells and tumor cells in the early stages of growth. However, at later stages of growth, tumor cells, through transcriptional inhibition, stop expressing TGF-β receptor type II (TGFβRII), causing them to no longer respond to the growth inhibitory effects of TGF-β [7] [8] [9] . Interestingly, tumor cells that are known to induce bone destruction express TGFβRII, suggesting that the tumor cells may reexpress the receptor once established in bone [10] . In bone metastases, TGF-β response is critical for the initiation and continuation of bone destruction. When tumor cells are genetically altered to no longer express TGFβRII, tumor bearing mice display a reduction in bone destruction [11] . This is in part through the ability of TGF-β to regulate the expression of the osteolytic factor, PTHrP, through the Smad and MAPK pathways [12] . In addition, TGF-β is known to be a critical component of the cellular response to tissue rigidity. This TGF-β mediated response to rigidity likely contributes in part to the biphasic and complicated regulation of TGF-β seen both in normal tissue and bone.
Tumor Produced Factors
Several tumor-produced factors have been studied by various groups through the years. Some of these include PTHrP, Runx2, interleukin-8 (IL-8), macrophage colonystimulating factor (M-CSF), and others. The effects of PTHrP in cancer are perhaps the best described. Professor T.J. Martin's group discovered in the 1990s that PTHrP was preferentially expressed when tumor cells metastasized to bone rather than soft tissue sites [13, 14] . Dr. Gregory Mundy's group has since shown that PTHrP expression is an important component of tumor-induced bone disease and that inhibiting its expression reduces bone destruction [11, 15, 16] . This production of PTHrP stimulates the osteoblasts to produce RANKL, which stimulates osteoclastmediated bone resorption [2, 5] . Similarly, Runx2, which is expressed by breast tumors, has been reported to stimulate the expression of RANKL by the tumor cells, which can lead to bone destruction [17, 18] . M-CSF has also been demonstrated to be expressed by breast and prostate cancer cells and stimulate bone destruction through RANKL. Other molecules that have been associated with bone resorption are the interleukins, specifically IL-8, which is expressed by some tumors cells and can stimulate bone destruction independently of RANKL [19, 20] . While other factors have been implicated in bone disease, there is strong pre-clinical evidence that the inhibition of PTHrP expression can reduce bone destruction [6, 12, 16, 21] . Due to this strong evidence, clinical trials were undertaken with antibodies for PTHrP; however, the results of these trials were never published.
PTHrP was initially discovered as a factor associated with humoral hypercalcemia of malignancy [22] , but also plays an important role developmentally. Specifically, PTHrP is critical for endochondral bone formation, where deletion of PTHrP leads to a short-limbed dwarfism phenotype [23] . It is also important during mammary development and lactation, and release during lactation is thought to induce bone resorption for the release of calcium from the bone [24, 25] In tumor cells, PTHrP is regulated by TGF-β [11, 12] and the Hedgehog transcription factor Gli2 [6, 15] . Most studies suggest that TGF-β is a primary regulator of PTHrP, but although TGF-β expression is higher in bone, it is also expressed in most other tissues in the body. Thus it is unclear whether the higher concentration of TGF-β in bone can account for the differential expression in tumorproduced PTHrP [33] . As shown in Fig. 1a , while mechanical stretch differs from cellular attachment to a rigid matrix, the mechanotransduction pathway is activated in both cases through the action of external forces on the cell. Thus, recent observations showing that Gli2 and PTHrP expression are upregulated on rigid matrices through both mechanically transduced and TGF-β signaling [4] are consistent with previous studies reporting increased PTHrP expression in response to mechanical stretch [31, 32] . Interestingly, PTHrP and Gli2 expression were increased on rigid (compared to compliant) 2D substrates, but the effect was blocked when TGF-β or mechanically transduced signaling was inhibited. A more detailed description of the proposed mechanism driving changes in TGF-β response due to matrix rigidity will be presented in the following sections, which may explain the increased expression of PTHrP when tumor cells become established in bone.
The Role of Matrix Rigidity in Regulating Cellular Outcomes
When tumor cells metastasize to bone, they are in contact with a mineralized extracellular matrix that is approximately 1,000,000 times more rigid than soft tissue. The bone extracellular matrix comprises several matrix proteins, including collagen, fibronectin (FN), osteonectin, osteopontin, and thrombospondin 2 [34] , each of which contributes to the structure and properties of the bone microenvironment. Integrin α v β 3 , which is a receptor for the bone matrix proteins osteopontin, FN, and vitronectin, has been identified as a critical integrin in breast cancer and prostate cancer skeletal metastasis [35] [36] [37] [38] [39] [40] [41] . Overexpression of α v β 3 in breast cancer cells has been associated with increased levels of bone metastasis, tumor burden, and subsequent osteolysis [36, [42] [43] [44] [45] . Considering the role of FN in tumor-induced bone disease, in vitro studies investigating the role of matrix rigidity on osteolytic gene expression have utilized FN as the matrix protein supporting binding of the tumor cells to the matrix [4, 46] . Alternatively, tumor cells may bind to the lining cells directly in contact with the bone through the bone stromal ligand osteopontin [47] , which is required for tumor cell colonization to bone [48] . It is unclear whether tumor cells directly contact the bone or whether they attach to cells lining the bone. Regardless of whether tumor cells are in direct or indirect (i.e., through stromal cells) contact with the bone, the forces experienced by tumor cells in the mineralized bone microenvironment are anticipated to be greater than in soft tissue.
Cells respond to the rigidity of the extracellular matrix through integrins clustered at adhesion sites, which provide a bond between the matrix and the cytoskeleton of the cell [49] . Thus the response of cells to the rigidity of the matrix is regulated by a variety of mechanisms, including the strength of the integrin-matrix bond, the pulling capacity on these bonds, and the sensitivity of the mechanotransduction system [50] . The rigidity of the extracellular matrix is known to regulate tumor cell invasiveness at the primary site [51] [52] [53] , and a recent in vitro study suggests that the rigid mineralized bone matrix contributes to the initiation of osteolytic gene expression by tumor cells when they become established in bone [46] . In this study, Gli2 and PTHrP expression increased when breast cancer cells were cultured on 2D substrates with elastic moduli exceeding that of the basement membrane (∼10,000 nN/μm2) [4, 46] . Considering that all the substrates were coated with the same surface concentration of FN, differences in gene expression could not be attributed to differences in composition. Since ROCK [4] and α v β 3 integrin are required for the increased osteolytic gene expression on rigid matrices, in a later section we review the role of integrins and ROCK in regulating the ability of the cell to sense the rigidity of the matrix.
The effects of the rigid mineralized bone extracellular matrix on expression of other factors associated with invasion and metastasis are largely unknown. The most relevant investigations providing evidence of other pathways that may respond to matrix rigidity are mechanical loading studies, where factors such as Wnt, IGF [54] , TGF-β, and BMP-2 [55] have been shown to be upregulated with increased mechanical loading. How expression of these factors changes with variations in matrix rigidity is unknown but is of great interest, since they have also been implicated in tumor-induced bone disease.
Measurement of Matrix Rigidity
The parameter frequently used to quantify the rigidity of tissues and synthetic matrices is the elastic (or Young's) modulus, which unlike compliance or stiffness is independent of the geometry of the material. As shown in Fig. 2 , the elastic modulus is defined by the initial slope of the stress (σ) versus strain curve and has SI units of N/m 2 or Pascal (Pa). As recently suggested [50, 56] , we will use the proposed units for stress of nN/μm 2 (equivalent to kPa) that are more natural for tissue. The elastic moduli of various tissues are listed in Table 1 . It is important to note that tissues, as well as natural and synthetic matrices used to investigate the effects of rigidity on cell fate, exhibit viscoelastic mechanical properties, where the relationship between stress and strain is not linear but dependent on the magnitude of the force and the time scale of the deformation [50] . However, for the typically small deformations (e.g., 100-150 nm [57, 58] ) relevant to mechanotransduction, the elastic modulus is a reasonable approximation for the rigidity of the matrix. In response to an applied external force, cells generate contractile traction forces against the matrix that are mediated by Rho-associated kinase (ROCK). Recent studies have suggested that in order for cells to respond to matrix rigidity, a threshold force must be obtained that generates a matrix displacement of approximately 100-150 nm [50, 57, 58] . Thus when cultured on rigid substrates, cells generate larger traction forces than on compliant substrates, which may be due to the fact that rigid substrates require larger contractile forces to maintain matrix strain [50, 59] .
Integrins Mediate Interactions Between the Cell and the Extracellular Matrix (ECM)
Integrins, a family of transmembrane receptors, are the primary mediator of adhesions between cells and the matrix [60] , and their function in mediating cell adhesion has been reviewed extensively [50, 61] . The extracellular domain of [50, 59] . As shown in the plot, both mRNA expression (red bars) and protein secretion (black bars) of PTHrP increased with the elastic modulus of the 2D substrate on which they were cultured. MRNA expression was measured at 24h by RT-PCR using 18S as an internal control. PTHrP protein secretion was measured in conditioned medium at 48h using a two-site immunoradiometric assay (IRMA) and normalized for cell number integrins binds to ligands in the matrix, such as fibronectin, vitronectin, or laminin [62, 63] , while the cytoplasmic domains bind to proteins associated with cytoskeletal linkage and signaling [61, 64] . Integrin binding to the ligands in the matrix results in integrin clustering and activation of enzymes including kinases (e.g., focal adhesion kinase (FAK)) and phosphatases (e.g., tyrosine phosphatase-α (RPTP-α)) that regulate signal transduction within the cell [50, 61] . RPTP-α can activate Src family kinases (SFKs) within about 300 ms after application of a force on fibronectin beads [65] [66] [67] . Phosphorylation of mitogen-activated protein kinase (MAPK) has also been reported to increase in response to mechanical stress, suggesting that integrins sense forces regulating gene expression by activation of the MAPK pathway [68] , which is known to be downstream of TGF-β signaling [69] .
At locations where integrins cluster on 2D substrates, other molecules are subsequently recruited to form focal adhesions [61] , which can result from the application of an external force (e.g., a cellular contractile force) to integrins [70] [71] [72] [73] . On a rigid substrate, the contractile force exerted by the cells is greater than the force generated on a compliant substrate, resulting in increased clustering of integrins [51] and reinforcement of the bonds between the integrins and cytoskeleton [74] . Molecules such as RPTP-α [73] , vinculin [71] , and talin [72] strengthen the links between integrins and the cytoskeleton in a force-dependent manner. Forces applied to the cell also activate the RhoA/ ROCK-mediated assembly of actomyosin stress fibers that exert contractile force and generate cytoskeletal tension [75] . Thus cells cultured on rigid substrates show upregulated integrin expression [76] , more stress fibers [76] , stable focal adhesions [59, 71] , and greater traction forces [51] . Conversely, cells cultured on compliant substrates show dynamic adhesions [59] and are not as spread [76] .
Materials for Investigating Mechanotransduction Pathways
Many studies investigating the effects of the rigidity of the matrix on cell migration, differentiation, and invasion have used 2D cell culture on hydrogel substrates, including Matrigel™ [77] , crosslinked gelatin [78] , and synthetic hydrogels [79] . Similarly, the invasiveness of cancer cells has been reported to increase with matrix rigidity when cultured on hydrogels [51, 52, 78, 80] . However, considering that the elastic modulus of hydrogel substrates is generally <100 nN/μm 2 , their applicability to the bone microenvironment, where the modulus of the mineralized extracellular matrix ranges from 17,100,000-28,900,000 nN/μm 2 [50] , may be limited.
Recent studies have investigated the effects of matrix rigidity on cellular outcomes over a range of elastic moduli that is more representative of the bone microenvironment. Both co-polymer chemistry and substrate rigidity were observed to regulate osteoblast differentiation of MG63 preosteoblast cells cultured on 2D acrylate-based co-polymer networks with elastic moduli ranging from 5,500-851,000 nN/μm 2 [81] . Another recent study has reported Fig. 2 Definitions of (a) the elastic modulus, E, and (b) stiffness, k. The stiffness is related to the modulus by the expression k=AE/L, where A is the cross-sectional area and L is the length of the sample. The modulus is a convenient parameter for describing the rigidity of a matrix because it is independent of the geometry of the test specimen 2 ). Inhibition of ROCK or the MAPK pathway decreased RUNX2 activity and delayed the expression of markers of osteoblast differentiation. To test the effects of substrate rigidity on osteolytic gene expression in tumor cells, we designed a 2D cell culture system using substrates with tunable elastic moduli [4] . Poly (acrylamide) (PAA) hydrogels were investigated as a model for breast tissue (0.8 nN/μm 2 ) [83] , poly(ester urethane) (PUR) films [84] as a model for tissues ranging from smooth muscle (5,000 nN/μm 2 ) to trabecular bone (8,700,000-11,400,000 nN/μm 2 ) [85] , and glass (67,000,000 nN/μm 2 ) as a model for cortical bone (17,100,000-28,900,000 nN/μm 2 ) [50] . Gli2 and PTHrP expression were lowest on PAA hydrogels and increased with modulus for values up to 1,000,000 nN/μm 2 , at which point it became constant (Fig. 1b) . However, many other genes associated with metastasis [86] to bone showed minimal changes in expression [4] . Interestingly, matrix rigidity regulated osteolytic gene expression for modulus values ranging from 1,000-1,000,000 nN/μm 2 , which exceeds that of areolar connective tissue and smooth muscle and approaches that of trabecular bone [4] .
Maximal Force Generation in Cells
Recent evidence suggests that the ability of the cell to sense substrate rigidity involves uniform displacement of the substrate [50] . Several studies suggest that cells sense rigidity based on whether a threshold force is obtained when the displacement of the substrate is in the range of 100-150 nm [50, 57, 58] . The magnitude of the elastic modulus of the substrate that would likely result in a displacement of 100 nm has been estimated to be 10 nN/ μm 2 [50] . A mechano-chemical coupling model has also been developed to physically describe cell adhesion and spreading mediated by the rigidity of the substrate based on the classical Bell-Dembo theory that cell adhesion is regulated by reversible receptor-ligand interactions [87, 88] . The model predicts that the force generated by the cells increases dramatically when cultured on substrates ranging from 1-100 nN/μm 2 , and that the adhesion strength equals ∼90% of the maximum value at 100 nN/μm 2 . Taken together, these studies suggest that cells are likely to be more responsive to the matrix when the rigidity is in the range of 1-100 nN/μm 2 , which is in agreement with a recent review reporting that actomyosin appeared diffuse for cells cultured on soft gels, while cells cultured on rigid (e.g., 30-100 nN/μm 2 ) gels or glass (67,000,000 nN/μm 2 ) showed stress fibers and strong focal adhesions [59] . Based on these observations, it has been suggested that cells cultured on substrates having a modulus equal to or greater than that of rigid gels (∼100 nN/μm 2 ) are in a state of isometric contraction [59] . It is interesting to note that this range is at least 1-2 orders of magnitude lower than the range of moduli over which osteolytic gene expression increases in MDA-MB-231 and RWGT2 tumor cells that metastasize to bone.
The Role of the Rigid Extracellular Matrix in Promoting Osteolytic Gene Expression
We have recently suggested that the rigid mineralized bone matrix, which is at least 1,000,000 times stiffer than soft tissue, plays a significant role in the initiation of osteolytic gene expression by tumor cells after they become established in bone [4, 46] . When MDA-MB-231 or RWGT2 tumor cells were cultured on rigid 2D substrates with moduli approaching those of mineralized bone tissue, PTHrP and Gli2 gene expression increased by 2-4-fold compared to culture on compliant substrates approximating soft tissue. This increase in gene expression on rigid substrates was mediated by Rho kinase (ROCK) and TGFβRII, but the details of the signaling mechanism remained unclear.
Recent studies have described the relationship between mechanically transduced and oncogenic signaling [51, 53] . Integrins function as mechanoreceptors [70] and mediate mechanotransduction by transferring forces to focal adhesions connecting integrins to the cytoskeleton [89] . Changes in the rigidity of the matrix alter the force balance in the cell, thereby creating a positive feed-back loop that can drive cell proliferation [53] . Cellular traction forces increase with matrix rigidity, resulting in activation of integrins and formation of focal adhesions, as well as stimulation of Rho/ROCK signaling and subsequent phosphorylation of myosin light chain (MLC), driving increased cell contractility, which feeds back to further increase the rigidity of the matrix. Interestingly, breast cancer cells cultured on relatively rigid gels showed increased expression of the undifferentiated malignant phenotype as well as increased Rho activity [51] . Furthermore, over-expression of constitutively active RhoV14 in normal mammary epithelial cells cultured on compliant matrices induced the malignant properties observed when the cells were cultured on rigid matrices. Similarly, blocking cell contractility via pharmacological inhibition of myosin II or ROCK abrogated the malignant phenotype observed on rigid gels. These observations suggest that the effect of matrix rigidity on cell transformation is driven by ROCK-generated contractility. However, inhibition of Erk was also observed to abrogate the malignant phenotype observed for cells over-expressing constitutively active RhoV14, as well as to reduce ROCKgenerated contractility, which supports the notion that crosstalk between the mechanotransducing Rho/ROCK and mitogenic EGFR/Erk pathways sustains a positive feed-back loop that may drive cell transformation.
As shown in Fig. 3 , our recent findings point to similar solid-state and soluble growth factor signaling pathways driving expression of osteolytic factors by tumor cells when they initially become established in the bone microenvironment. As discussed in Section "The Bone MicroEnvironment", active α v β 3 integrin in breast tumor cells binds to FN [90] , thereby enabling cancer cells to adhere to and interact with bone matrix to control early events in bone metastasis [45] . Furthermore, α v β 3 integrin is required by osteoclasts to resorb the mineralized bone matrix, and antagonists of α v β 3 integrins have been successfully used to inhibit osteoclasts and reduce bone loss in models of osteoporosis and metastatic bone disease [45, 91] . Thus blocking α v β 3 has the potential to block osteolysis in addition to inhibiting the stimulatory effect of TGFβ on PTHrP expression.
Crosstalk between integrins and growth factor receptors also regulates tumor growth and invasion [90] . Integrin α v β 3 interacts physically with the TGFβRII, resulting in TGF-β-mediated stimulation of MAPKs and Smad2/3-mediated gene transcription in mammary epithelial cells (MECs) during epithelial-mesenchymal transition (EMT) [92] . Consequently, we hypothesized that the rigid bone matrix drives changes in ROCK-generated contractility and integrin-dependent signaling that are distinct from the primary site, and that these changes specific to bone may alter TGF-β signaling within metastatic tumor cells to initiate expression of factors required for osteolysis. In our preliminary studies we have found that MDA-MB-231 cells The rigid matrix alters TGF-β signaling by promoting increased clustering of α v β 3 and TGFβRII, followed by Src phosphorylation of TGFβRII to activate MAPK signaling [92] , an important upstream effecter of PTHrP [69] . Thus cross-talk between mechanosensing ROCK and soluble TGF-β signaling pathways drives expression of Gli2 and PTHrP cultured on 2D substrates approximating the rigidity of bone showed an increase in mRNA expression of β 3 integrin subunit and increased phosphorylation of MLC [4] compared to cells grown on a compliant substrate. Data from other groups has suggested an interaction between TGFβRII and the β 3 integrin subunit [92] , and our unpublished data suggest that this integrin-receptor interaction increases on rigid matrices. These observations suggest that mechanotransduction alters TGF-β signaling within osteolytic tumor cells, as show in the solid-state signaling box in Fig. 3a .
Integrins are essential for translating the rigidity of the microenvironment into intracellular signaling pathways. Cells respond to mechanical tension through the activation of integrins, Rho-GTPases, and SFKs [93] . In soft tissues, cells respond to mechanical stimulus by activating SFKs [66, 94, 95] . Thus changes in both the expression and clustering of integrins, as well as integrin-mediated signaling pathways induced by the rigid mineralized bone matrix, can activate SFKs, which might be essential for the ability of the cell to sense the rigidity of the matrix [96] . Specific inhibitors to Src tyrosine kinases, which are required to regulate integrin-cytoskeleton interactions, have shown promise in preclinical studies, reducing both tumor burden and incidence in bone [97, 98] as well as metastasis to bone [99] . After activation, SFKs promote coupling of the cytoskeleton to integrins through talin [100] [101] [102] , which enables mechanical forces on the integrins to engage the integrin/matrix catch bond [50] . While the detailed mechanisms governing translation of mechanical forces sensed within cell-matrix adhesions to biochemical changes are not completely known, changes in the conformation of integrins in response to a rigid matrix are thought to result in tension-dependent changes in conformation of integrinassociated proteins, such as SFK, p130Cas and vinculin [96] .
In addition to their role in mediating mechanotransduction, SFKs are also known to regulate TGF-β signaling [50] . Src phosphorylation of TGFβRII in response to TGFβRII and α v β 3 clustering has been implicated in EMT and is known to activate MAPK signaling [103] , an important upstream effector of PTHrP [69] . Our preliminary data indicate that Src and α v β 3 are required for the stimulation of PTHrP and Gli2 through ROCK [4] . Similarly, the increased association of β 3 integrin subunit with TGFβRII on rigid substrates suggests that the rigid mineralized bone matrix activates MAPK signaling in MDA-MB-231 cells [103] . Taken together, these data suggest that cross-talk between mechanosensing ROCK and soluble TGF-β signaling pathways drives expression of Gli2 and PTHrP, as summarized in Fig. 3b . This mechanism is similar to that proposed for tumor cell invasion and proliferation mediated by cross-talk between Rho/ROCK and EGFR/Erk pathways in the primary site [51, 53] , but there is a significant difference. In soft tissue, forces resulting from ROCK-generated contractility can drive cytoskeletal remodeling, resulting in stiffening of the matrix surrounding the tumor [52, 83] that alters integrindependent signaling within the tumor cells [52, 104, 105] . This positive feedback loop driving matrix remodeling in the primary site can lead to a 100-fold increase in matrix rigidity [51] . In contrast, in the bone microenvironment tumor cells interact with a rigid matrix that is at least 100,000,000-fold stiffer than the primary site. Consequently, the rigid bone matrix is anticipated to drive changes in ROCK-generated contractility and integrindependent signaling immediately upon establishment of the tumor cells in the bone microenvironment.
Clinical Perspectives
A variety of therapies have been approved or are under clinical investigation for the treatment of metastatic bone disease, as summarized in Fig. 3 . Bisphosphonates are currently the clinical standard of care for treating patients with bone metastases, and have been demonstrated in clinical trials to be safe and efficacious by reducing the risk of osteoporotic fractures [106] . While they have been tremendously successful in the treatment of osteoporosis and tumor-induced bone disease, they do not directly target the tumor cells, which are the root cause of the problem. Furthermore, some patients fail bisphosphonate treatment, and the recent discovery of clinical complications observed with long term bisphosphonate treatments, including osteonecrosis of the jaw and atypical subtrochanteric fractures, has made these drugs less ideal clinically [1, 107, 108] . The emerging drug for clinical use, Denosumab or XGEVA (Amgen), which targets RANKL, has been demonstrated to reduce bone turnover and increase bone density in clinical studies [109] . Interestingly, this drug seems to have the capability of inhibiting tumor growth, yet this seems likely to be an indirect effect [110] . However, XGEVA™ also presents safety risks, including hypocalcemia and osteonecrosis of the jaw, though the prevalence is unclear due to limited clinical data [1] .
Inhibition of TGF-β has been another active area of recent pre-clinical studies, which have thus far been very successful, with several groups demonstrating that inhibition of TGF-β reduces metastasis to soft tissues [111, 112] and bone [113] . In addition to direct effects on the tumor, treatement of healthy (i.e., tumor-free) mice with the TGF-β inhibitors 1D11 (Genzyme, Cambridge, MA) and SD-208 (Scios, Inc., Sunnyvale, CA) increases bone density and biomechanical properties as well as numerous measures of bone quality (e.g., trabecular bone architecture and mineral: collagen ratio) [114, 115] . Blocking TGF-β also increased the numbers of osteoblasts and decreased the numbers of osteoclasts in the bone marrow of healthy mice. These data suggest that a TGF-β inhibitor may be an ideal drug for bone metastases, since it can both inhibit tumor growth and improve bone quality. However, their use may be complicated in patients due to the biphasic effects of TGF-β in tumor growth and its effects throughout the body on normal cells [116] . Specifically, in genetic mouse models in which TGF-β signaling is stimulated, TGF-β inhibits formation of mammary tumors at early stages, but can promote metastasis of tumors at later stages. These observations suggest that while TGF-β inhibitors may block bone resorption in patients with bone metastases, they could possibly increase tumor cell growth in the primary site. This would be a particularly important issue for patients that still have a primary tumor or have multiple metastases. Therefore, when considering these drugs for clinical use the effects on other cell types or tumors need to be considered thoroughly.
The limitations of all these drugs underscore the need for more specific inhibitors of tumor growth in bone. Inhibiting downstream molecules, such as mechanotransduction inhibitors or Gli2, could potentially be an alternative treatment strategy. The ROCK inhibitors Fasudil (Tocris Bioscience, Ellisville, MO) and Y-27632 have been used successfully in preclinical models of pulmonary and cardiac disease. Furthermore, clinical studies have shown that Fasudil is a safe and efficacious treatment for patients with severe pulmonary hypertension [117] . Fasudil is currently being used clinically for the treatment of cerebral vasospasms, and is also being evaluated in clinical studies for other cardiovascular uses, indicating that the drug is well tolerated by patients [118] . Considering that ROCK is required for Gli2 and PTHrP expression, as well as the clinical safety and efficacy of Fasudil in cardiovascular applications, ROCK inhibitors such as Fasudil may be a potential alternative strategy for treatment of tumor-induced bone disease.
Additionally, based on our current data, inhibition of the mechanotransduction pathway makes an attractive target. Potential targets include pathways with well-established inhibitors such as Src and Integrins. Similar to TGF-β, these drugs have both been tested in normal mice and been shown to inhibit osteoclast activity [41, 119, 120] . Our data suggest that their inhibition may also prevent PTHrP and tumor growth, therefore suggesting that these drugs will target both the tumor and the bone microenvironment. Consistent with other studies implicating α v β 3 integrin in tumor progression [121] , our unpublished data suggest that α v β 3 integrin is the prevalent integrin complex involved in tumor response to matrix rigidity [122] . Therefore, monoclonal antibodies have been developed to inhibit integrin activity [121] , such as LM-609, which has been shown to inhibit tumor growth in pre-clinical studies [123] . Etaracizumab (the humanized form of LM609) is currently in clinical trials for metastatic melanoma, where it has been used successfully [124] . Other drugs in clinical trials include CNTO 95 (intetumumab) for treatment of melanoma and angiosarcoma [125] , as well as cilengitide for the treatment of Glioblastomas [126] .
Alternatively, we are highly optimistic that Gli antagonists (GANT) will provide a more specific approach for targeting the tumor and subsequent bone disease. The GANT drugs have been used in pre-clinical trials in many different tumor types, and have been very effective at reducing tumor burden [127] . Our recently published data demonstrate that Gli2 inhibition nearly eliminates tumor growth in bone, while reducing PTHrP expression in tumors that are present, which results in a reduction in tumor-induced bone disease [6] . Therefore, in addition to inhibiting tumor growth, they are anticipated to block both the mechanically transduced and TGF-β mediated expression of PTHrP. Furthermore, considering the limited expression of Gli proteins in adults, effects on normal tissues should be minimal.
In the last several years, many potential targets for inhibiting tumor-induced bone disease have been studied. Each of these compounds have their benefits and drawbacks. It is likely that a combination of multiple drugs will likely be the best approach. Which of these targets will succeed is difficult to determine from the current preclinical data, but we anticipate that a drug combination targeting both the micro-environment and the tumor growth will be most effective.
Conclusions
Over the past 20 years our view of the "vicious cycle" has adapted to include many different growth factors and cell types. Recent studies have indicated that the rigidity of the microenvironment can control tumor cell gene expression and behavior. While previous studies have been limited to osteolytic tumor cells, the rigid bone microenvironment is anticipated to alter gene expression of osteoblastic tumor cells as well. Future work in this area is needed to better understand the pathways involved in the response of tumor cells to rigidity, which will facilitate the development of improved clinical targets that not only inhibit tumor-induced bone destruction, but that can also kill the tumor cells residing in bone or prevent tumors from establishing in bone. Further investigation of mechanotransduction pathways are expected to reveal new interactions that will continue to expand our understanding of the vicious cycle. 
